Lacerol Cor Retard

Diltiazem, the active ingredient in Lacerol Cor Retard, is a calcium channel blocker presented as a prolonged‑release oral tablet for oral use. It treats hypertension and angina and is used for rate control in atrial fibrillation in adult patients.

GNH USA supplies Lacerol Cor Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diltiazem acts on the cardiovascular system to manage several related conditions.

- Hypertension: lowers elevated blood pressure by relaxing vascular smooth muscle. - Angina pectoris: reduces frequency and severity of chest pain by improving myocardial oxygen supply. - Stable angina: enhances exercise tolerance and decreases anginal episodes. - Rate control in atrial fibrillation: slows ventricular response by decreasing conduction through the atrioventricular node.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the lower extremities due to fluid retention. - Constipation: reduced bowel motility leading to hard stools. - Nausea: mild upset stomach or feeling of queasiness.

Serious or Rare Side Effects: - Severe bradycardia: markedly slow heart rate requiring medical attention. - Atrioventricular block: impaired electrical conduction that may need pacing. - Significant hypotension: dangerous drop in blood pressure causing faintness. - Liver enzyme elevation: abnormal liver function tests indicating hepatic stress. - Allergic reactions: rash, itching, or swelling that may progress to anaphylaxis. - Heart failure exacerbation: worsening symptoms in susceptible patients.

Before initiating therapy, consider the following precautions.

- Monitor blood pressure: check regularly to ensure therapeutic control. - Assess heart rate: watch for bradycardia, especially in patients on other rate‑controlling agents. - Evaluate liver function: adjust use if hepatic impairment is present. - Use cautiously in heart failure: may worsen symptoms due to negative inotropic effect. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Diltiazem may interact with several medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase diltiazem levels. - Beta‑blockers: combined use may cause excessive bradycardia or heart block. - Digoxin: diltiazem can raise digoxin concentrations, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Antacids: may reduce diltiazem absorption; separate dosing by at least 2 hours. - NSAIDs: can attenuate the antihypertensive effect of diltiazem, requiring blood pressure monitoring.